48.26

2.07% 1.19

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $48.26, with a volume of 173.22K. It is up +2.07% in the last 24 hours and up +11.58% over the past month. Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Previous Close:

$47.07

Open:

$46.98

24h Volume:

173.22K

Relative Volume:

0.44

Market Cap:

$3.05B

Revenue:

$88.55M

Net Income/Loss:

$-157.85M

P/E Ratio:

-17.49

EPS:

-2.76

Net Cash Flow:

$-137.92M

1W Performance:

-0.92%

1M Performance:

+11.58%

6M Performance:

+28.46%

1Y Performance:

+236.68%

1-Day Range:

$46.34

$48.21

1-Week Range:

$42.62

$48.56

52-Week Range:

$13.85

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

181

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

KYMR's Discussions on Twitter

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

08:13 AM

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey

08:13 AM

07:29 AM

Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times

07:29 AM

03:54 AM

Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

03:54 AM

Nov 04, 2024

UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Nov 04, 2024

Immunology to take front seat at Kymera - The Pharma Letter

Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia

Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India

Nov 04, 2024

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St

Nov 04, 2024

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance

Nov 04, 2024

FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World

Nov 04, 2024

Nov 03, 2024

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Nov 03, 2024

Nov 02, 2024

Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Nov 01, 2024

The Latest Analyst Ratings For Kymera Therapeutics - Benzinga

Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat

Nov 01, 2024

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Nov 01, 2024

B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia

Nov 01, 2024

Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK

Nov 01, 2024